Profile data is unavailable for this security.
About the company
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
- Revenue in EUR (TTM)6.81bn
- Net income in EUR151.80m
- Incorporated1987
- Employees23.74k
- LocationGrifols SAParque Empresarial Can Sant JoanAvinguda de la Generalitat, 152-158SANT CUGAT DEL VALLES 08174SpainESP
- Phone+34 935710000
- Fax+34 935710267
- Websitehttps://www.grifols.com/
Holder | Shares | % Held |
---|---|---|
Brandes Investment Partners LPas of 31 Jan 2024 | 13.48m | 5.16% |
The Vanguard Group, Inc.as of 30 Sep 2024 | 8.78m | 3.36% |
Capital International Ltd.as of 30 Sep 2024 | 7.07m | 2.70% |
Cobas Asset Management SGIIC SAas of 30 Sep 2024 | 2.79m | 1.07% |
FIL Investments Internationalas of 31 Jul 2024 | 2.00m | 0.76% |
AzValor Asset Management SGIIC SAas of 30 Jun 2024 | 1.79m | 0.68% |
Robeco Institutional Asset Management BVas of 30 Sep 2024 | 1.66m | 0.63% |
Santander Asset Management SA SGIICas of 30 Jun 2024 | 1.30m | 0.50% |
HSBC Global Asset Management (France) SAas of 31 Oct 2024 | 1.25m | 0.48% |
Sabadell Asset Management SA SGIIC SUas of 30 Jun 2024 | 1.13m | 0.43% |